Hepatitis E - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Hepatitis E - Pipeline Review, H1 2018’, provides an overview of the Hepatitis E pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hepatitis E, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatitis E and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Hepatitis E

The report reviews pipeline therapeutics for Hepatitis E by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Hepatitis E therapeutics and enlists all their major and minor projects

The report assesses Hepatitis E therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Hepatitis E

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hepatitis E

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hepatitis E pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Cadila Healthcare Ltd

Chongqing Zhifei Biological Products Co Ltd

CPL Biologicals Pvt Ltd

Gilead Sciences Inc

Cadila Healthcare Ltd

Chongqing Zhifei Biological Products Co Ltd

CPL Biologicals Pvt Ltd

Gilead Sciences Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hepatitis E – Overview

Hepatitis E – Therapeutics Development

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hepatitis E – Overview

Hepatitis E – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hepatitis E – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hepatitis E – Companies Involved in Therapeutics Development

Cadila Healthcare Ltd

Chongqing Zhifei Biological Products Co Ltd

CPL Biologicals Pvt Ltd

Gilead Sciences Inc

Hepatitis E – Drug Profiles

hepatitis E vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hepatitis E vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hepatitis E vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hepatitis E vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sofosbuvir – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hepatitis E – Dormant Projects

Hepatitis E – Product Development Milestones

Featured News & Press Releases

Mar 27, 2013: Changchun Company Initiates Phase I Study Of New Hepatitis E Recombinant Vaccine

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Hepatitis E, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products ...

List of Tables

Number of Products under Development for Hepatitis E, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Hepatitis E – Pipeline by Cadila Healthcare Ltd, H1 2018

Hepatitis E – Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2018

Hepatitis E – Pipeline by CPL Biologicals Pvt Ltd, H1 2018

Hepatitis E – Pipeline by Gilead Sciences Inc, H1 2018

Hepatitis E – Dormant Projects, H1 2018

List of Figures

List of Figures

Number of Products under Development for Hepatitis E, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products ...

List of Figures

Number of Products under Development for Hepatitis E, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports